EUVIMEDEUVIMED entdecken
Crossref

Discovery of a High-Potency Balanced GLP-1/GIP Dual Agonist by Molecular Dynamics Evolution

Nan Zhang iD, Li Teng, Xiang Yu, Zhiyong Wang, Zhiping Zhang, Zhao Dong, Dongzhou Liu

Journal of Medicinal Chemistry · 28.05.2026 · 69 (10) · 11672-11686

DOI: 10.1021/acs.jmedchem.6c00466 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 13.05.2026. Verfasst von Nan Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Huadong Global R&D Center, Hangzhou 310011, P. R. of China. Hauptthemen laut MEDLINE: Molecular Dynamics Simulation, Receptors, Gastrointestinal Hormone, Glucagon-Like Peptide 1, Drug Discovery. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Zhejiang Key Laboratory of New Drug Intelligent Innovation for Metabolic Diseases, Zhejiang University, "Pioneer" and "Leading Goose" R&D Program of Zhejiang.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HDM1005 (poterepatide), a novel highly potent GLP-1/GIP dual agonist, was engineered via computational alanine scanning and rational acylation design. Nonacylated HDM1005 (P001) showed stable receptor binding and higher affinity than nonacylated Tirzepatide in molecular dynamics simulations and MMGBSA calculation. Alanine scanning and steric clash analysis (radius of gyration) guided proper K24/28 acylation sites on P001. Optimized linker and acyl chain design at K24 precisely tuned bioactivity and extended long-acting performance (T1/2 ∼ 20.3-23.1 h vs Tirzepatide's 9.21 h in mice). HDM1005 exerted 3-fold more potent HbAlc reduction in db/db mice and superior weight loss in DIO mice (39.97% vs 34.47%) versus Tirzepatide, yielding enhanced metabolic benefits, plus preferential fat loss with lean mass preservation in obese mice. It exhibited a favorable safety profile with a NOAEL of 5 mg/kg. With enhanced receptor binding, extended pharmacodynamic activity, and superior efficacy, HDM1005 represents a potential best-in-class therapeutic agent for metabolic disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Molecular Dynamics SimulationReceptors, Gastrointestinal HormoneGlucagon-Like Peptide 1Drug DiscoveryGlucagon-Like Peptide-1 Receptor AgonistsAnimalsMiceHumansStructure-Activity RelationshipMaleMice, Inbred C57BL

Substanzen

Receptors, Gastrointestinal Hormonegastric inhibitory polypeptide receptorGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Huadong Global R&D Center, Hangzhou 310011, P. R. of China.

ORCID-Profile: Nan Zhang

Förderung

  • Zhejiang Key Laboratory of New Drug Intelligent Innovation for Metabolic Diseases, Zhejiang University
  • "Pioneer" and "Leading Goose" R&D Program of Zhejiang

Zitieren

APA

Zhang, N., Teng, L., Yu, X., Wang, Z., Zhang, Z., Dong, Z., & Liu, D. (2026). Discovery of a High-Potency Balanced GLP-1/GIP Dual Agonist by Molecular Dynamics Evolution. Journal of Medicinal Chemistry, 69(10), 11672-11686. https://doi.org/10.1021/acs.jmedchem.6c00466

Vancouver

Zhang N, Teng L, Yu X, Wang Z, Zhang Z, Dong Z, et al. Discovery of a High-Potency Balanced GLP-1/GIP Dual Agonist by Molecular Dynamics Evolution. Journal of Medicinal Chemistry. 2026;69(10):11672-11686. doi:10.1021/acs.jmedchem.6c00466

BibTeX
@article{Zhang2026,
  author = {Zhang, Nan and Teng, Li and Yu, Xiang and Wang, Zhiyong and Zhang, Zhiping and Dong, Zhao and Liu, Dongzhou},
  title = {Discovery of a High-Potency Balanced GLP-1/GIP Dual Agonist by Molecular Dynamics Evolution},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {10},
  pages = {11672--11686},
  doi = {10.1021/acs.jmedchem.6c00466}
}
Kostenlos starten →